Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.
Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
Hasılat
453
99
127
116
109
106
Hasılat Artışı (YoY)
8%
-7%
17%
14%
9%
22%
Satınalma Maliyeti
178
38
50
46
42
38
Brüt Kâr
275
61
76
69
67
67
Satış, Genel ve İdari
279
65
73
70
71
63
Araştırma ve Geliştirme
225
65
61
47
50
60
İşletme Giderleri
505
130
134
118
121
124
Diğer Finansman Gelirleri (Giderleri)
3
0
0
0
3
1
Kâr Öncesi Gelir
-179
-49
-53
-35
-40
-48
Kira Vergisi Gideri
-1
1
-2
0
0
0
Net Kâr
-178
-51
-50
-35
-40
-48
Net Income Growth
Kâr Artışı
-28.99%
6%
-38%
-15%
-50%
-9%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
1,107.39
1,107.39
1,106.17
1,102.07
1,091.93
1,080.82
Hisse Değişimi (Yıllık Üst Üste)
2%
2%
8%
12%
12%
11%
EPS (Diluted)
-0.16
-0.04
-0.04
-0.03
-0.03
-0.04
EPS Artışı
-35%
3%
-43%
-23%
-55%
-19%
Öz sermaye akışı
-132
-34
-27
-36
-35
-65
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
60.7%
61.61%
59.84%
59.48%
61.46%
63.2%
Faaliyet Kâr Marjı
-50.77%
-69.69%
-45.66%
-41.37%
-49.54%
-52.83%
Kâr Marjı
-39.29%
-51.51%
-39.37%
-30.17%
-36.69%
-45.28%
Özsermaye Karlılık Oranı
-29.13%
-34.34%
-21.25%
-31.03%
-32.11%
-61.32%
EBITDA
-215
-66
-55
-45
-51
-53
EBITDA Marjinali
-47.46%
-66.66%
-43.3%
-38.79%
-46.78%
-50%
D&A EBITDA için
15
3
3
3
3
3
Faaliyet Kârı
-230
-69
-58
-48
-54
-56
Faaliyet Kâr Marjı
-50.77%
-69.69%
-45.66%
-41.37%
-49.54%
-52.83%
Verilen Vergi Oranı
0.55%
-2.04%
3.77%
0%
0%
0%
Follow-Up Questions
¿Cuáles son los estados financieros clave de Zai Lab Ltd?
Según el último estado financiero (Form-10K), Zai Lab Ltd tiene un total de activos de $0, una ganancia neta kayıp de $0
¿Cuáles son los ratios financieros clave para ZLAB?
El ratio corriente de Zai Lab Ltd es 0, el margen neto es 0, las ventas por acción son $0.
¿Cómo se desglosan los ingresos de Zai Lab Ltd por segmento o geografía?
Zai Lab Ltd en büyük gelir kaynağı Innovative Therapies olup, en son kar bildiriminde geliri 3,587,394,608 dir. Coğrafi olarak, Greater China and United States , Zai Lab Ltd için ana pazar olup, geliri 3,587,394,608 dir.
¿Es rentable Zai Lab Ltd?
hayır, según los últimos estados financieros, Zai Lab Ltd tiene una ganancia neta kayıp de $0
¿Tiene Zai Lab Ltd alguna deuda?
hayır, Zai Lab Ltd tiene una deuda de 0
¿Cuántas acciones en circulación tiene Zai Lab Ltd?
Zai Lab Ltd tiene un total de acciones en circulación de 0